Trial NCT01727336

View at ClinicalTrials.gov 
Org. Study IDs: A041-04
Secondary IDs: ACE-041

Last trial update was posted on 2022-10-06

MeSH Interventions

Axitinib

MeSH Conditions

Carcinoma Carcinoma, Renal Cell

Other Conditions

Advanced Renal Cell Carcinoma

Stopping Reasons

The study was terminated by the sponsor following unblinding of the Progression Free Survival endpoint.

Limitations And Caveats

All 131 patients in Part 2 discontinued from the study; the most frequent reasons were (i) study terminated at the discretion of the sponsor [86 patients (65.6%)] and (ii) death [36 patients (27.5%)]. The discontinuations prior to planned sample collections, as outlined in the protocol schedule of events, precluded the ability to carry out all planned analyses, including but not limited to PK analyses. Dalantercept PK in patients with advanced cancer has been reported previously.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID